This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Clinical Trials
GALE
A Phase III, Open-Label, Multi-Centre, Extension Study to Evaluate the Long-Term Safety and Efficacy of Pegcetacoplan in Subjects with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD).
Overview
A Phase III, Open-Label, Multi-Centre, Extension Study to Evaluate the Long-Term Safety and Efficacy of Pegcetacoplan in Subjects with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD).
- Principal Investigator
Professor Robyn Guymer AM
A Phase III, Open-Label, Multi-Centre, Extension Study to Evaluate the Long-Term Safety and Efficacy of Pegcetacoplan in Subjects with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD).
- Principal Investigator
Learn more
View this study on ClinicalTrials.gov
See the ClinicalTrials.gov database listing for more detailed information about this study.